David A. Siegel Spero Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.74 - $7.44 $118,220 - $1.19 Million	159,757 Added 974.13%	176,157 $131,000
Q1 2022 May 16, 2022	BUY	$7.87 - $15.15 $129,068 - $248,460	16,400 New	16,400 $143,000
Q2 2021 Aug 16, 2021	SELL	$12.22 - $15.79 $299,732 - $387,297	-24,528 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$13.23 - $21.48 $68,796 - $111,696	5,200 Added 26.9%	24,528 $361,000
Q4 2020 Feb 16, 2021	SELL	$11.65 - $22.07 $24,465 - $46,347	-2,100 Reduced 9.8%	19,328 $375,000
Q3 2020 Nov 16, 2020	BUY	$8.96 - $14.12 $45,696 - $72,012	5,100 Added 31.23%	21,428 $239,000
Q2 2020 Aug 14, 2020	BUY	$7.27 - $14.18 $118,704 - $231,531	16,328 New	16,328 $221,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $40.7M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.